Table 2.

Evaluation of IMC-18F1 and MF1 combined with cytotoxic agents compared with monotherapies against established MDA-MB-231 human breast tumor xenografts

Agent*Dose (mg/kg)Mean tumor volume (mm3 ± SE)%T/C (d)P (RM-ANOVA)
ControlNA1296 ± 116NA
IMC-18F1 and MF120/40857 ± 8969 (29)0.005 vs control
5-FU/LV125/65919 ± 7373 (29)0.008 vs control
IMC-18F1 and MF1 + 5-FU/LV20/40 + 125/65648 ± 4551 (29)<0.0001 vs control
<0.02 vs antibodies
0.0004 vs 5-FU/LV
IMC-18F1 and MF120/40857 ± 8969 (29)0.005 vs control
Doxorubicin3597 ± 7254 (29)<0.0001 vs control
IMC-18F1 and MF1 + doxorubicin20/40 + 3382 ± 4330 (29)<0.0001 vs control
<0.0001 vs antibodies
0.01 vs doxorubicin
ControlNA1,148 ± 138NA
IMC-18F1 and MF120/40854 ± 11274 (45)0.1 vs control
Cyclophosphamide100777 ± 8068 (45)0.001 vs control
IMC-18F1/MF1 + cyclophosphamide20/40 + 100479 ± 7242 (45)<0.0001 vs control
<0.0001 vs antibodies
0.005 vs cyclophosphamide
  • Abbreviations: RM-ANOVA, repeated measures ANOVA; NA, not available.

  • * IMC-18F1 (20 mg/kg) and MF1 (40 mg/kg) were administered i.p. thrice weekly. 5-FU/LV (125/62 mg/kg) and cyclophosphamide (100 mg/kg) were given i.p. once weekly. Doxorubicin (3 mg/kg) was given i.p. twice weekly.

  • T/C, tumor growth inhibition, where T is the mean tumor volume of treated group and C is the mean tumor volume of control group on the designated day.

  • IMC-18F1 and MF1.